Загрузка...
Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib is a tyrosine kinase inhibitor that displays antitumor activity against anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer. However, crizotinib-associated interstitial lung disease (ILD) has been reported as an infrequent, but potentially fatal complication. We...
Сохранить в:
| Опубликовано в: : | Mol Clin Oncol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
D.A. Spandidos
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4888013/ https://ncbi.nlm.nih.gov/pubmed/27284449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.838 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|